VelaVigo

Incubated by Panacea Venture and was founded by Dr. Jing Li, the former head of early-stage discovery at WuXi Biologics. Dr. Li successfully led over 200 discovery programs during his tenure at Wuxi, and several programs became foundational drug candidates for major biotech companies worldwide. The company functions as a major discovery engine for antibodies, including new constructs and technology platforms for bi-specific and multi-specific antibodies as well as antibody drug conjugates. Programs cover multiple therapeutic areas